Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (podocytes) | 0.10 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 54 Parkinson's papers of 514 | 0.47 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 7558
Sealed predictions
- LMX1B in dopamine neurons, braak-0.72 (p 0.028) → -0.12 (p 0.768)receipt 7564
In the sealed studies
Swarm cases
receipt 7564: LMX1B in dopamine neurons, braak
- power
- full sample -0.39 (p 0.109, n 18), 95% CI -0.73 to +0.09. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.36 (p 0.148, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.53 (p 0.025, n 18). not the mix.
- skeptic
- leave-one-out range -0.56 to -0.32, sign flips 0; without severely affected donors -0.39 (p 0.109, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LMX1B in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts